APLS Q3 2019 Earnings — Apellis Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena

APLSApellis Pharmaceuticals, Inc.

$2B

Q3 2019 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$0

Gross Profit

-$70M

Operating Income

-$70M

Net Income

-$70M

EPS (Diluted)

$-1.10

QoQ Revenue Growth

NaN%

Cash Flow

Operating Cash Flow

-$54M

Free Cash Flow

-$54M

Stock-Based Comp.

$5M

Balance Sheet

Total Assets

$466M

Total Liabilities

$327M

Stockholders' Equity

$140M

Cash & Equivalents

$434M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$0	$0	—
Gross Profit	-$70M	-$36M	-95.4%
Operating Income	-$70M	-$36M	-95.4%
Net Income	-$70M	-$36M	-94.1%